Cargando…

The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease

OBJECTIVE: We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. METHODS: We linked Alberta health databases to identify patients aged ≥ 18 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Dat T., Palfrey, Dan, Welsh, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333236/
https://www.ncbi.nlm.nih.gov/pubmed/33484443
http://dx.doi.org/10.1007/s41669-021-00257-8
_version_ 1783732984077090816
author Tran, Dat T.
Palfrey, Dan
Welsh, Robert
author_facet Tran, Dat T.
Palfrey, Dan
Welsh, Robert
author_sort Tran, Dat T.
collection PubMed
description OBJECTIVE: We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. METHODS: We linked Alberta health databases to identify patients aged ≥ 18 years with HRCVD between fiscal year (FY) 2012 and FY2016. The first HRCVD event was the index event. Patients were categorized into (1) primary prevention patients and (2) secondary prevention patients at the index event and were followed until death, they moved out of the province, or they were censored at March 2018. We calculated the resource use and costs for each of the 5 years after the index event. RESULTS: The study included 459,739 HRCVD patients (13,947 [3%] were secondary prevention patients). The secondary prevention patients were older (median age 61 years vs. 55 years; p < 0.001), and there were fewer females in this group (30.4% vs. 51.3%; p < 0.001). The total healthcare costs in the first year decreased over time (FY2012: 1.16 billion Canadian dollars (CA$); FY2016: CA$1.05 billion; p < 0.001). An HRCVD patient incurred CA$12,068, CA$5626, and CA$4655 during the first, second, and fifth year, respectively (p for trend < 0.001). During the first year, healthcare costs per secondary prevention patient (CA$36,641) were triple that for a primary prevention patient (CA$11,299; p < 0.001), primarily due to higher hospitalization costs in secondary prevention patients (CA$26,896 vs. CA$6051; p < 0.001). CONCLUSIONS: The healthcare costs for HRCVD patients were substantial but decreased over time. The costs were highest in the year following the index event and decreased thereafter. Secondary prevention patients incurred higher costs than the primary prevention patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00257-8.
format Online
Article
Text
id pubmed-8333236
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83332362021-08-20 The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease Tran, Dat T. Palfrey, Dan Welsh, Robert Pharmacoecon Open Original Research Article OBJECTIVE: We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. METHODS: We linked Alberta health databases to identify patients aged ≥ 18 years with HRCVD between fiscal year (FY) 2012 and FY2016. The first HRCVD event was the index event. Patients were categorized into (1) primary prevention patients and (2) secondary prevention patients at the index event and were followed until death, they moved out of the province, or they were censored at March 2018. We calculated the resource use and costs for each of the 5 years after the index event. RESULTS: The study included 459,739 HRCVD patients (13,947 [3%] were secondary prevention patients). The secondary prevention patients were older (median age 61 years vs. 55 years; p < 0.001), and there were fewer females in this group (30.4% vs. 51.3%; p < 0.001). The total healthcare costs in the first year decreased over time (FY2012: 1.16 billion Canadian dollars (CA$); FY2016: CA$1.05 billion; p < 0.001). An HRCVD patient incurred CA$12,068, CA$5626, and CA$4655 during the first, second, and fifth year, respectively (p for trend < 0.001). During the first year, healthcare costs per secondary prevention patient (CA$36,641) were triple that for a primary prevention patient (CA$11,299; p < 0.001), primarily due to higher hospitalization costs in secondary prevention patients (CA$26,896 vs. CA$6051; p < 0.001). CONCLUSIONS: The healthcare costs for HRCVD patients were substantial but decreased over time. The costs were highest in the year following the index event and decreased thereafter. Secondary prevention patients incurred higher costs than the primary prevention patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00257-8. Springer International Publishing 2021-01-23 /pmc/articles/PMC8333236/ /pubmed/33484443 http://dx.doi.org/10.1007/s41669-021-00257-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Tran, Dat T.
Palfrey, Dan
Welsh, Robert
The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
title The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
title_full The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
title_fullStr The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
title_full_unstemmed The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
title_short The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
title_sort healthcare cost burden in adults with high risk for cardiovascular disease
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333236/
https://www.ncbi.nlm.nih.gov/pubmed/33484443
http://dx.doi.org/10.1007/s41669-021-00257-8
work_keys_str_mv AT trandatt thehealthcarecostburdeninadultswithhighriskforcardiovasculardisease
AT palfreydan thehealthcarecostburdeninadultswithhighriskforcardiovasculardisease
AT welshrobert thehealthcarecostburdeninadultswithhighriskforcardiovasculardisease
AT trandatt healthcarecostburdeninadultswithhighriskforcardiovasculardisease
AT palfreydan healthcarecostburdeninadultswithhighriskforcardiovasculardisease
AT welshrobert healthcarecostburdeninadultswithhighriskforcardiovasculardisease